vilobelimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies 5761 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • vilobelimab
  • gohibic
  • IFX-1
  • CaCP29
Vilobelimab is a chimeric monoclonal IgG4-kappa antibody that binds to C5a with a dissociation constant of 9.6pM and blocks its interaction with the C5a receptor. C5a is part of the complement system and is activated as part of the innate immune response initiating an inflammatory cascade that includes increased vascular permeability, coagulation, proinflammatory cytokine release, and recruitment and activation of neutrophils and other myeloid cells.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 13, 2025 EMA InflaRx GmbH

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AJ10 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Complement inhibitors
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D051056 Complement Inactivating Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

L04AJ Complement inhibitors 10 drugs
avacopancrovalimab-akkzdanicopaneculizumabiptacopanpegcetacoplanpozelimabravulizumabsutimlimabzilucoplan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
SARS-CoV2-induced acute respiratory distress syndrom indication 840539006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Complement C5 Secreted BINDING AGENT Kd 9.59 DRUG LABEL DRUG LABEL

External reference:

IDSource
2250440-41-4 SECONDARY_CAS_RN
CHEMBL2109636 ChEMBL_ID
C000706656 MESH_SUPPLEMENTAL_RECORD_UI
11346 IUPHAR_LIGAND_ID
DB16416 DRUGBANK_ID
4042164 VANDF
4042165 VANDF
C5392705 UMLSCUI
CHEBI:754373 CHEBI
11304 INN_ID
D11838 KEGG_DRUG
137254326 PUBCHEM_CID
366270 MMSL
41391 MMSL
d10030 MMSL
019374 NDDF
F5T0RF9ZJA UNII
2639620 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
GOHIBIC HUMAN PRESCRIPTION DRUG LABEL 1 83000-110 INJECTION 10 mg INTRAVENOUS Emergency Use Authorization 27 sections